A 49-year-old obese man presents to his primary care physician for a routine follow-up after being diagnosed with type 2 diabetes mellitus three weeks ago during an employee health screening. He reports no polyuria or polydipsia but notes fatigue with moderate exertion. He has a 10-year history of hypertension managed with lisinopril and denies any history of chronic kidney disease or liver disease. His BMI is 34 kg/m², blood pressure is 138/86 mmHg, and heart rate is 78 beats per minute. Fasting glucose is 168 mg/dL, hemoglobin A1c is 8.0%, serum creatinine is 0.9 mg/dL, and eGFR is 92 mL/min/1.73m². His physician initiates first-line pharmacotherapy that primarily decreases hepatic gluconeogenesis and is associated with weight loss rather than weight gain. Which of the following drugs was most likely prescribed?
- A)Semaglutide
- B)MetforminGABARITO
- C)Pioglitazone
- D)Glyburide
- E)NPH insulin
Explicação
Metformin is first line pharmacotherapy for most patients with type 2 diabetes and works mainly by decreasing hepatic gluconeogenesis while improving insulin sensitivity. It is generally weight neutral to weight reducing, which fits this obese patient with pre... Ver explicação completa e trilha adaptativa →